vanadates has been researched along with imatinib mesylate in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chromic, J; Hoelzer, D; Hofmann, WK; Koschmieder, S; Koyama, N; Myloch, S; Nürnberger, H; Ottmann, OG; Portero-Robles, I; Rossmanith, T; Tyagi, S | 1 |
1 other study(ies) available for vanadates and imatinib mesylate
| Article | Year |
|---|---|
Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Phosphorylation; Piperazines; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatases; Protein-Tyrosine Kinases; Pyrimidines; Structure-Activity Relationship; Vanadates | 2006 |